By Fineline Cube 
Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) delivered robust first-half 2026 financial results on July 23, 2026, with group sales rising 6% to CHF 30,364 million (USD 37.2 billion) at constant exchange rates (CER). The company reported core operating profit growth of 10% to CHF 11,856 million (USD 14.5 billion), driven by sustained momentum in its pharmaceutical portfolio and steady diagnostics demand.
Financial Highlights – H1 2026
| Metric | Result | Growth (CER) |
|---|---|---|
| Group Sales | CHF 30,364M (USD 37.2B) | +6% |
| Core Operating Profit | CHF 11,856M (USD 14.5B) | +10% |
| Pharmaceutical Sales | CHF 23,629M (USD 28.9B) | +6% |
| Diagnostics Sales | CHF 6,735M (USD 8.2B) | +3% |
| Top 5 Growth Drivers | CHF 11.0B | +12% |
Pharmaceutical Portfolio Performance
- Key Growth Drivers: Roche’s top five pharmaceutical products delivered exceptional performance:
- Xolair (omalizumab): allergic asthma, chronic hives, food allergies
- Hemlibra (emicizumab): haemophilia A
- Ocrevus (ocrelizumab): multiple sclerosis
- Phesgo (trastuzumab/pertuzumab): breast cancer
- Vabysmo (Faricimab): severe eye diseases
- Combined Impact: These five products generated CHF 11.0 billion in sales, representing 12% growth at CER and accounting for nearly half of total pharmaceutical revenue
- Therapeutic Diversity: Strong performance across immunology, hematology, neurology, oncology, and ophthalmology demonstrates portfolio resilience and reduced dependency on single therapeutic areas
Diagnostics Segment Analysis
- Growth Trajectory: Diagnostics sales increased 3% to CHF 6,735 million, reflecting steady demand across key segments
- Demand Drivers: Growth was fueled by continued investment in:
- Immunodiagnostic solutions
- Clinical chemistry platforms
- Pathology systems
- Molecular diagnostic technologies
- Market Position: Roche maintains its leadership position in the global diagnostics market, benefiting from integrated healthcare trends and precision medicine adoption
Forward Guidance & Strategic Outlook
- Full-Year Expectations: Roche reaffirms its 2026 guidance:
- Group sales growth: mid-single-digit range (CER)
- Core EPS growth: high-single-digit range (CER)
- Shareholder Returns: The company plans a further dividend increase in Swiss francs, continuing its commitment to returning value to shareholders
- Pipeline Momentum: Strong H1 performance provides confidence in the company’s ability to execute on late-stage pipeline assets and maintain growth trajectory beyond 2026
- Currency Impact: All growth figures reported at constant exchange rates, providing clear visibility into underlying business performance independent of forex volatility
Market Context & Competitive Positioning
- Pharmaceutical Industry Trends: Roche’s diversified portfolio strategy contrasts with peers facing patent cliffs, positioning the company favorably in the current market environment
- Innovation Investment: Continued strong profitability enables sustained R&D investment, with the company maintaining one of the industry’s highest research intensity ratios
- Integrated Healthcare Model: The combination of pharmaceuticals and diagnostics creates unique competitive advantages in precision medicine and companion diagnostic development
- Geographic Diversification: Balanced exposure across North America, Europe, and international markets provides stability against regional economic fluctuations
Forward‑Looking Statements
This brief contains forward-looking statements regarding financial performance, growth expectations, and strategic initiatives. Actual results may differ due to regulatory developments, competitive pressures, and macroeconomic conditions.-Fineline Info & Tech